Effects of Oral Tranexamic Acid Following Total Knee Arthroplasty
NCT ID: NCT06479161
Last Updated: 2024-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
80 participants
INTERVENTIONAL
2024-06-10
2025-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will review prospectively collected data, including patient demographic information, surgeon, use of oral tranexamic acid (TXA) or placebo regimen, and postoperative outcomes up to 3 months after surgery. Collaboration with Saint Francis' pharmacy team will be performed to ensure appropriate blinded administering of the oral TXA and placebo medication.
This will be a double blinded study, with both patient and surgeon blinded to study group.
6.0 TXA dosing protocol TXA day of surgery \[All patients\]
* Administer 1-gram IV TXA intraoperatively at the start of the case (hold for history of stent within 1 year of surgery)
o AND
* Administer 1-gram IV TXA postoperatively before leaving PACU (hold for history of stent within 1 year of surgery)
o OR
* Exception: Administer 2 grams TXA in 50cc normal saline topically during the case for patients with a history of stent placed within one year of surgery.
TXA postoperative day (POD) 1-3 \[Experimental group\]
* Administer 1.95 grams oral (3- 650 mg tablets) TXA each morning for three days following surgery.
* Patients discharged home before POD 3 will be sent home with remaining oral TXA doses.
Placebo POD 1-3 \[Control group\]
* Administer oral placebo (3 tablets) each morning for three days following surgery.
* Patients discharged home before POD 3 will be sent home with remaining oral placebo doses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Collaboration with Saint Francis' pharmacy team will be performed to ensure appropriate blinded administering of the oral TXA and placebo medication.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TXA
\- 1.95 grams oral TXA (tranexamic acid) (3- 650 mg tablets) administered postop day one, postop day two and postop day three. Compounded by registered pharmacist and labeled with subject name and instructions for use.
Tranexamic acid
1.95 grams oral
Placebo
\- 3 tablets administered postop day one, postop day two and postop day three. Compounded by registered pharmacist and labeled with subject name and instructions for use.
Tranexamic acid
1.95 grams oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tranexamic acid
1.95 grams oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performed by participating Connecticut Joint Replacement Institute (CJRI) surgeons (Dr. Matthew Grosso, Dr. Robert McAllister, Dr. Chad Daniel, Dr. Eric Silverstein, Dr. Alex Dukas, Dr. Michael Joyce, Dr. Brett Wasserlauf).
* Male and female patient age 18-89
* Primary diagnosis of knee osteoarthritis
Exclusion Criteria
* No exclusion based on gender
* Patients \<18 and \>89 years old
* Exclusion for IV oral tranexamic acid (TXA):
* TXA allergy - there are NO absolute contraindications for TXA use.
* History of stent placed within one year of surgery - patient will receive topical TXA as an alternative.
* Exclusion for oral TXA:
o Actively treated cancer or deep vein thrombosis (DVT)
* Chronic opioid use (opioid use within the 4 weeks prior to surgery)
* Allergies to nonsteroidal Anti-inflammatory drugs (NSAIDs) and acetaminophen
* Patients with clinically significant drug interactions
* Pre-existing neuropathy
* Current or previous venous thrombosis (DVT or venous stasis disease)
* Immuno-compromised secondary to medical condition
* Immune-suppressive medications, chemotherapy
* Pregnancy, breast feeding
* History of pain catastrophizing. Major depressive disorder
* History of suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
* Currently on a neuroleptic agent \[e.g., gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) etc.\].
* Non-English speaking and reading patient populations
* Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that, in the opinion of the investigator, renders the subject medically unstable or complicates the subject's post-operative course.
18 Years
89 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Matthew Grosso, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthew Grosso, MD
Director, Quality and Outcomes Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Trinity Health Of New England/CT Joint Replacement Institute
Hartford, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gina Panek, BS
Role: primary
Czarina Weinz
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SFH 24-05
Identifier Type: -
Identifier Source: org_study_id